Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

LoneStar Heart Raises $20 Million in Round Led by Hong Kong PE Firm

publication date: Oct 9, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
LoneStar Heart of California has raised up to $20 million in a milestone-based equity financing, which the company will use to support clinical development its lead product, Algisyl-LVR. The product, considered a medical device, is a biopolymer that is implanted into the left ventricle wall of the heart to treat advanced heart failure. The financing was led by Themes Investment Partners, a Hong Kong PE fund focused on China markets. The capital will be used to conduct clinical trials in Europe (already underway), followed by China. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...